[Molecular mechanisms of oncogenic transformation: what's new?].
During the past two years, new molecular targets have been discovered which link cell cycle, cell proliferation and cellular growth. It has become more and more evident that whereas gain-of-function mutations in specific genes can lead to cancer, genomic instability plays also an important role in tumour progression. With examples taken from the recent literature, we describe in this short review crucial findings on the molecular mechanisms controlling cell cycle and proliferation. We illustrate how specific combinations of proto-oncogenes alterations can result in tissue-specific tumours. Finally, impairment of the interactions of a cancer cell with its surrounding neighbours is also shown to participate in the progression toward aggressive phenotypes.
Blanchard
Jean-Marie
JM
Institut de génétique moléculaire, CNRS, UMR5535, IFR24, 1919, route de Mende, 34293 Montpellier Cedex 5.
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000378:metabolism; D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle / Q000502:physiology*; D002455:Cell Division / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D019938:Cyclin D1 / Q000502:physiology; D019927:Cyclin E / Q000502:physiology; D051357:Cyclin-Dependent Kinase 2; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000502:physiology; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000502:physiology; D016213:Cyclins / Q000378:metabolism; D018450:Disease Progression; D004351:Drug Resistance; D016044:Fusion Proteins, bcr-abl / Q000502:physiology; D006801:Humans; D051379:Mice; D009154:Mutation / Q000502:physiology*; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000502:physiology; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D019006:Neural Cell Adhesion Molecules / Q000502:physiology; D017239:Paclitaxel / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000502:physiology; D011836:Radiation Tolerance; D051381:Rats; D019699:Thrombospondins / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology; D014402:Tuberous Sclerosis / Q000235:genetics / Q000473:pathology
D000972:Antineoplastic Agents, Phytogenic; C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse; C493958:Cdkn1a protein, rat; D019927:Cyclin E; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D009363:Neoplasm Proteins; D019006:Neural Cell Adhesion Molecules; D019699:Thrombospondins; D016212:Transforming Growth Factor beta; D019938:Cyclin D1; D016044:Fusion Proteins, bcr-abl; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; C495893:Cdk2 protein, mouse; C495892:Cdk2 protein, rat; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; D017239:Paclitaxel